Abstract 106P
Background
The deficiency of F-Box and leucine rich repeat protein 5 (FBXL5), an iron-sensing ubiquitin ligase, triggers carcinogenesis of hepatocellular carcinoma (HCC) due to iron overload. However, the expression of FBXL5 and its clinical implication have not been elucidated in HCC.
Methods
We investigated FBXL5 protein expression using immunohistochemistry in HCC tissue samples of two institutes, Samsung Medical Center and Hallym University Sacred Heart Hospital. X-tile software was used for the optimization of cut-off value. We evaluated the association between FBXL5 expression and various clinicopathological parameters. For external validation, The Cancer Genome Atlas (TCGA) cohort was used.
Results
Expression of FBXL5 less than 5% of tumor was designated as low expression group and the remaining referred as high expression group. Low FBXL5 expression was found in 78 cases out of 395 cases (19.7%) and associated with non-viral etiology (P = 0.024). Low FBXL5 expression group showed inferior disease-specific overall survival (OS; P = 0.013) and recurrence free survival (RFS; P=0.005) compared to high FBXL5 expression group. Similar to our cohort, cases with low FBLX5 mRNA level showed inferior OS and RFS (P<0.001 and P=0.002, respectively) than those with high FBLX5 mRNA level in TCGA cohort.
Conclusions
Low expression of FBXL5 is associated with non-viral HCC patients and associated with inferior disease-specific OS and RFS. FBXL5 can be used as a potential prognostic markers and therapeutic target for non-viral HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
48P - Long-term clinical outcomes after the second metastasectomy in patients (pts) with resected metastatic colorectal cancer (mCRC)
Presenter: Songji Choi
Session: Poster viewing 02
49P - Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy: Final results of the phase II RE-ExPEL study
Presenter: Thorsten Goetze
Session: Poster viewing 02
50P - Linear tumor regression of rectal cancer in daily MRI during preoperative chemoradiotherapy: An insight of tumor regression velocity for personalized cancer therapy
Presenter: Sea-Won Lee
Session: Poster viewing 02
51P - Efficacy and safety of sintilimab as first-line therapy in patients with microsatellite instability-high metastatic colorectal cancer: A real-world study
Presenter: Caiyun Nie
Session: Poster viewing 02
53P - Baseline PET/CT deep radiomics signature apply for identifying bevacizumab sensitivity of RAS-mutant colorectal cancer liver metastases patients
Presenter: Wenju Chang
Session: Poster viewing 02
54P - Efficacy of total neoadjuvant therapy (TNT) in rectal cancer: A meta-analysis of randomized controlled trials
Presenter: Yakup Ergün
Session: Poster viewing 02
55P - Biodegradable and biocompatible 3D-printed scaffolds loaded with chemotherapy drugs: A new horizon for treatment of colon cancer with diffuse intraperitoneal metastasis
Presenter: Amirhosein Kefayat
Session: Poster viewing 02
56P - Clinico-pathological profile of adolescent and young adult colorectal cancer patients: Multicentre collaborative registry data from India
Presenter: Soumya Surath Panda
Session: Poster viewing 02